Amgen has said the deal with Galapagos could provide it with promising lead candidates for Amgen’s discovery programs over the next two years.
Under the terms of the extended agreement, Galapagos will receive an upfront fee of $2.4 million as a payment for 2007 research costs and may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses.
The initial collaboration involves the identification of lead candidates against multiple ion channel targets. The new agreement expands this collaboration to include all classes of targets, including ion channel, GPCR and kinase targets.
Additionally, the agreement will now include the supply of BioFocus DPI’s compound collection comprising 700,000 synthetic small molecules and its natural product compound collection containing 145,000 products.